Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

FDA approves pembrolizumab for relapsed/refractory PMBCL

FDA Press Announcement, June 15, 2018; Keytruda Prescribing Information (Drugs@FDA)

The FDA has approved (pembrolizumab) Keytruda for the treatment of relapsed or refractory primary mediastinal large B-cell lymphoma (PMBCL).

Indications: Keytruda, a programmed death receptor-1 (PD-1)-blocking antibody is indicated for the treatment of adult and pediatric patients with refractory PMBCL or who have relapsed after 2 or more prior lines of therapy. It is not recommended for treatment of patients with PMBCL who require urgent cytoreductive therapy.

Keytruda also is indicated for the treatment of melanoma, non-small cell lung cancer, head and neck squamous cell carcinoma, classical Hodgkin lymphoma, urothelial carcinoma, microsatellite instability-high cancer, gastric cancer, and cervical cancer.

Dosage and administration: For adults, the recommended dose is 200 mg every 3 weeks. In pediatric patients, the recommended dose is 2 mg/kg every 3 weeks, with a maximum dose of 200 mg.

Efficacy and safety: Based on a multicenter, open-label, single-arm trial of 53 patients with relapsed or refractory PMBCL (KEYNOTE-170; NCT02576990), the overall response rate was 45%, with 11% of patients seeing a complete response and 34% seeing a partial response.

Side effects/risks: The most common adverse reactions to pembrolizumab were musculoskeletal pain, upper respiratory tract infection, pyrexia, fatigue, cough, dyspnea, diarrhea, nausea, arrhythmia, and headache. In total, a quarter of patients with adverse reactions required systemic treatment with a corticosteroid and 26% of patients had serious adverse reactions.

Citation:

FDA Press Announcement, June 15, 2018

Keytruda Prescribing Information (Drugs@FDA)

This Week's Must Reads

Corticosteroid use poses risk of febrile neutropenia, Chao CR et al. J Natl Compr Canc Netw. 2018;16(10):1201-8

5F9 plus rituximab looks durable in NH, Advani R et al. N Engl J Med. 2018;379:1711-21

Systematic review examines sickle cell trait complications, Naik RP et al. Ann Intern Med. 2018 Oct 30. doi:10.7326/M18-1161

Cardiovascular risks in hemophilia A, Humphries TJ et al. Adv Med Sci. 2018;63(2):329-33

Study evaluates rapid bacterial testing of platelets, Booth AL et al. AABB18, Abstract INV4

Must Reads in Aggressive Lymphomas

Corticosteroid use poses risk of febrile neutropenia, Chao CR et al. J Natl Compr Canc Netw. 2018;16(10):1201-8

5F9 plus rituximab looks durable in NH, Advani R et al. N Engl J Med. 2018;379:1711-21

Age is an independent predictor of mortality after transplant, Kyriakou C et al. Biol Blood Marrow Transplant. 2018 Sep 13. doi: 10.1016/j.bbmt.2018.08.025

Complications in EPOCH-R versus R-CHOP, David RJ et al. Clin Lymphoma Myeloma Leuk. 2018 Aug 29. doi: 10.1016/j.clml.2018.08.014

Cardiac assessment before doxorubicin treatment , Enns DL et al. Mayo Clin Proc Innov Qual Outcomes. 2018 Aug 3;2(3):277-85